Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors.
Abu-Arja, MH; Osorio, DS; Lassaletta, A; Graham, RT; Coven, SL; Stanek, JR; Bouffet, E; Finlay, JL; Abdelbaki, MS.
Pediatric Blood and Cancer.
2022;
69.
Pediatric Gliosarcoma With and Without Neurofibromatosis Type 1: A Whole-exome Comparison of 2 Patients.
Graham, RT; Bell, EH; Webb, A; Zhao, Y; Timmers, C; Fleming, JL; Sells, BE; Robison, NJ; Palmer, JD; Finlay, JL; et al.
Journal of Pediatric Hematology/Oncology.
2021;
43:e1201-e1204.
Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma.
Graham, RT; Abu-Arja, MH; Stanek, JR; Cappellano, A; Coleman, C; Chi, S; Cooney, T; Dhall, G; Ellen, JG; Finlay, JL; et al.
Pediatric Blood and Cancer.
2021;
68.
Venous thromboembolism in children with central nervous system tumors: Comparison of an institutional cohort to a national administrative database.
Graham, RT; Coven, SL; Stanek, JR; Folta, A; Hollingsworth, EW; Finlay, JL; Kumar, R.
Pediatric Blood and Cancer.
2021;
68.
MBCL-06. SUCCESSFUL SALVAGE OF DESMOPLASTIC NODULAR MEDULLOBLASTOMA PATIENTS TREATED ON ACNS1221.
Graham, RT; Conley, S; Finlay, JL; AbdelBaki, MS.
Neuro-Oncology.
2018;
20:i118-i118.
LGG-33. MEK-INHIBITOR MONOTHERAPY TO TREAT CONCURRENT OPTIC GLIOMA AND METASTATIC NEUROBLASTOMA IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1 (NF1).
Belsky, J; Graham, R; Leonard, J; Finlay, J; Jones, J; Boué, D; Ranalli, M; AbdelBaki, M.
Neuro-Oncology.
2018;
20:i111-i111.
HGG-30. PEDIATRIC GLIOSARCOMA WITH AND WITHOUT NEUROFIBROMATOSIS TYPE 1: A WHOLE-EXOME COMPARISON OF TWO PATIENTS.
Graham, RT; Bell, EH; Webb, A; Timmers, C; Robison, N; Palmer, J; Finlay, JL; Chakravarti, A.
Neuro-Oncology.
2018;
20:i95-i95.
Breaking Down Blood: Pediatric Immune Thrombocytopenia and Autoimmune Hemolytic Anemia in the Emergency Department.
Graham, R; Rose, MJ.
Clinical Pediatric Emergency Medicine.
2018;
19:122-130.
RARE-28. MALIGNANT TRANSFORMATION OF A LOW-GRADE MIDLINE GLIOMA WITH CONCOMITANT BRAFv600E AND H3.3K27 MUTATIONS.
Graham, R; AbdelBaki, MS; Finlay, JL.
Neuro-Oncology.
2017;
19:vi216-vi216.